These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33991706)

  • 1. Use of the angiogenic biomarker profile to risk stratify patients with fetal growth restriction.
    Arenas GA; Tang NY; Mueller A; Lopes Perdigao J; Kaur H; Abramowicz JS; Mussatt K; Yeo KJ; Rana S
    Am J Obstet Gynecol MFM; 2021 Jul; 3(4):100394. PubMed ID: 33991706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential plasma angiogenic factors levels in women with suspected preeclampsia.
    Baltajian K; Bajracharya S; Salahuddin S; Berg AH; Geahchan C; Wenger JB; Thadhani R; Karumanchi SA; Rana S
    Am J Obstet Gynecol; 2016 Jul; 215(1):89.e1-89.e10. PubMed ID: 26827880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma soluble fms-like tyrosine kinase 1 to placental growth factor ratio of 11.5 multiples of median predicts preeclampsia with severe features within 2 weeks of testing.
    Espinoza J; Calsavara VF; Kilpatrick S; Rana S; Costantine MM; Boggess K; Wylie BJ; Moore Simas TA; Louis JM; Gaw SL; Murtha A; Wiegand S; Gollin Y; Singh D; Silver RM; Durie DE; Panda B; Norwitz ER; Burd I; Plunkett B; Scott RK; Lemoine E; Thadhani R; Karumanchi SA
    Am J Obstet Gynecol; 2024 Sep; 231(3):363.e1-363.e11. PubMed ID: 38825028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of imminent preeclampsia at 35-37 weeks gestation.
    Ciobanu A; Wright A; Panaitescu A; Syngelaki A; Wright D; Nicolaides KH
    Am J Obstet Gynecol; 2019 Jun; 220(6):584.e1-584.e11. PubMed ID: 30738886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High early pregnancy body mass index is associated with alterations in first- and second-trimester angiogenic biomarkers.
    Beck C; Allshouse A; Silver RM; Grobman WA; Simhan H; Haas D; Reddy UM; Blue NR
    Am J Obstet Gynecol MFM; 2022 May; 4(3):100614. PubMed ID: 35283347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble fms-like tyrosine kinase to placental growth factor ratio in different stages of early-onset fetal growth restriction and small for gestational age.
    Garcia-Manau P; Mendoza M; Bonacina E; Garrido-Gimenez C; Fernandez-Oliva A; Zanini J; Catalan M; Tur H; Serrano B; Carreras E
    Acta Obstet Gynecol Scand; 2021 Jan; 100(1):119-128. PubMed ID: 32860218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study.
    MacDonald TM; Tran C; Kaitu'u-Lino TJ; Brennecke SP; Hiscock RJ; Hui L; Dane KM; Middleton AL; Cannon P; Walker SP; Tong S
    BMC Pregnancy Childbirth; 2018 Aug; 18(1):354. PubMed ID: 30170567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal serum levels of soluble fms-like tyrosine kinase-1 and placental growth factor at 20 and 28 weeks of gestational age and the risk of spontaneous preterm birth.
    Sovio U; Gaccioli F; Cook E; Charnock-Jones DS; Smith GCS
    Am J Obstet Gynecol; 2023 Aug; 229(2):164.e1-164.e18. PubMed ID: 36758709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of placental growth factor alone or in combination with soluble fms-like tyrosine kinase-1 or maternal factors in detecting preeclampsia in asymptomatic women in the second and third trimesters: a systematic review and meta-analysis.
    Chaemsaithong P; Gil MM; Chaiyasit N; Cuenca-Gomez D; Plasencia W; Rolle V; Poon LC
    Am J Obstet Gynecol; 2023 Sep; 229(3):222-247. PubMed ID: 36990308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertension.
    Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
    Am J Obstet Gynecol; 2021 Sep; 225(3):305.e1-305.e14. PubMed ID: 33812812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world evidence for the utility of serum soluble fms-like tyrosine kinase 1/placental growth factor test for routine clinical evaluation of hospitalized women with hypertensive disorders of pregnancy.
    Burns LP; Potchileev S; Mueller A; Azzi M; Premkumar A; Peterson J; Rausch A; Gonzalez M; Silasi M; Karumanchi SA; Thadhani R; Rana S
    Am J Obstet Gynecol; 2024 Jul; ():. PubMed ID: 39029547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The additive role of angiogenic markers for women with confirmed preeclampsia.
    Suresh S; Patel E; Mueller A; Morgan J; Lewandowski WL; Verlohren S; von Dadelszen P; Magee LA; Rana S
    Am J Obstet Gynecol; 2023 May; 228(5):573.e1-573.e11. PubMed ID: 36356699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes.
    Lai J; Syngelaki A; Nicolaides KH; von Dadelszen P; Magee LA
    Am J Obstet Gynecol; 2021 May; 224(5):518.e1-518.e11. PubMed ID: 33166504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world data on the clinical use of angiogenic factors in pregnancies with placental dysfunction.
    Dathan-Stumpf A; Czarnowsky V; Hein V; Andraczek T; Stepan H
    Am J Obstet Gynecol; 2022 Feb; 226(2S):S1037-S1047.e2. PubMed ID: 33892922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prediction of fetal death with a simple maternal blood test at 20-24 weeks: a role for angiogenic index-1 (PlGF/sVEGFR-1 ratio).
    Chaiworapongsa T; Romero R; Erez O; Tarca AL; Conde-Agudelo A; Chaemsaithong P; Kim CJ; Kim YM; Kim JS; Yoon BH; Hassan SS; Yeo L; Korzeniewski SJ
    Am J Obstet Gynecol; 2017 Dec; 217(6):682.e1-682.e13. PubMed ID: 29037482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble fms-like tyrosine kinase-1/placental growth factor ratio at 36 weeks' gestation: association with spontaneous onset of labor and intrapartum fetal compromise in low-risk pregnancies.
    Farina A; Cavoretto PI; Syngelaki A; Adjahou S; Nicolaides KH
    Am J Obstet Gynecol; 2024 Aug; ():. PubMed ID: 39181498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A longitudinal analysis of angiotensin II type 1 receptor antibody and angiogenic markers in pregnancy.
    Aggarwal S; Sunderland N; Thornton C; Xu B; Hennessy A; Makris A
    Am J Obstet Gynecol; 2017 Feb; 216(2):170.e1-170.e8. PubMed ID: 27793555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First trimester serum angiogenic and anti-angiogenic factors in women with chronic hypertension for the prediction of preeclampsia.
    Nzelu D; Biris D; Karampitsakos T; Nicolaides KK; Kametas NA
    Am J Obstet Gynecol; 2020 Apr; 222(4):374.e1-374.e9. PubMed ID: 31705883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal vascular-placental axis in the third trimester in women with gestational diabetes mellitus, hypertensive disorders, and unaffected pregnancies.
    Chatzakis C; Papavasiliou D; Mansukhani T; Nicolaides KH; Charakida M
    Am J Obstet Gynecol; 2024 Aug; ():. PubMed ID: 39218286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
    Holme AM; Roland MC; Henriksen T; Michelsen TM
    Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.